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Abstract
L-chicoric acid (L-CA) is a potent inhibitor of HIV integrase (IN) in vitro. In this report, the effects of a glycine to serine mutation at
position 140 (G140S) on HIV IN and its effects on IN inhibitor resistance are described. HIV containing the G140S mutation showed a delay
in replication. Using real-time polymerase chain reaction, the delay was secondary to a failure in integration. The mutant protein (ING140S)
was attenuated approximately four-fold for catalysis under equilibrium conditions compared to wild-type IN (INWT) and attenuated five-fold
in steady-state kinetic analysis of disintegration. Fifty percent inhibitory concentration assays were performed with IN inhibitors against both
IN proteins in disintegration and strand transfer reactions. ING140S was resistant to both L-CA and L-731,988, a diketoacid. HIV containing
the mutation was resistant to both inhibitors as well. The G140S mutation attenuates IN activity and confers resistance to IN inhibitors,
suggesting that diketoacids and L-CA interact with a similar binding site on HIV IN.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Integration, catalyzed by the viral enzyme integrase (IN),
is a required step in the life cycle of the human immuno-
deficiency virus (HIV) (Sakai et al., 1993). Mutation of
critical residues within IN results in non-productive infec-
tions characterized by short-term, low-level expression of
some viral proteins (Stevenson et al., 1990), a failure to
produce progeny virions (LaFemina et al., 1992; Sakai et
al., 1993), and the eventual circularization and degradation
of reverse-transcribed viral cDNA (Wiskerchen and
Muesing, 1995). A relatively small number of potent inhib-
itors of IN in vitro have been described to date and few have
possessed antiviral activity at non-toxic concentrations in
cell culture (reviewed in Pommier and Neamati, 1999; Rob-
inson, 1998).
IN is comprised of three separately folded functional
domains as determined by structural, complementation,
and mutational analyses (Reviewed in Andrake and
Skalka, 1996; Rice et al., 1996). The central catalytic
core domain of HIV IN contains three amino acid residues,
Asp64, Asp116, and Glu152, in a spatial arrangement of
DX39–58DX35E, which is invariant for retroviral IN’s, as
well as IN’s of yeast retrotransposons and some bacterial
transposases (Kulkosky et al., 1992). These residues coor-
dinate an absolutely required divalent metal cation (Mn2
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or Mg2) (Bujacz et al., 1996a; Bujacz et al., 1996b; Gold-
gur et al., 1998). The sequences of the amino- and carboxyl-
terminal domains of IN are less conserved (Johnson et al.,
1986).
As a first step for integration, IN removes the two ter-
minal nucleotides from the 3 end of each LTR. This endo-
nucleolytic cleavage, termed 3 end processing, occurs ad-
jacent to a highly conserved CpA dinucleotide located at
each viral 3 end (Brown et al., 1989; Fujiwara and Mizuu-
chi, 1988; Roth et al., 1989). The processed viral DNA ends
are then covalently inserted into the DNA of the infected
cell by a concerted cleavage-ligation reaction termed strand
transfer (Brown et al., 1989; Fujiwara and Mizuuchi, 1988).
Integration is likely completed by the actions of the host cell
DNA repair machinery (Miller, et al., 1995), thus producing
a stable, integrated provirus.
The in vivo activities of IN can be measured in vitro by
utilizing purified recombinant IN as well as 32P end-labeled
oligonucleotide substrates with sequences derived from the
HIV LTR (Bushman and Craigie, 1991; Chow, 1997; Chow
and Brown, 1994b; Chow et al., 1992) (Fig. 1). Oligonu-
cleotide assays of both 3 end processing and strand transfer
have been utilized to demonstrate the requirements for in-
tegration (Bushman and Craigie, 1991; Sherman et al.,
1992; Sherman and Fyfe, 1990). The reversal of integration,
termed disintegration, can be measured utilizing both Y-
shaped and dumbbell -shaped oligonucleotide substrates
(Chow, 1997) (Fig. 1). All four substrates have been used to
identify inhibitors of IN, while the disintegration substrate
has been useful in separating inhibition of the catalytic
activities of IN from inhibition of other IN activities such as
DNA binding (Robinson et al., 1996a).
L-chicoric acid (L-CA) (see Structures) is a potent in-
hibitor of IN in vitro (Robinson et al., 1996a; Robinson et
al., 1996b), which also inhibits viral replication at non-toxic
concentrations (Robinson et al., 1996a; Robinson et al.,
Fig. 1. Oligonucleotide substrates for in vitro IN assays. Oligonucleotide substrates for the 3 end processing/ strand transfer assay are complementary, 21
nucleotide oligomers with sequences derived from the U5 region of the HIV-1 LTR (V1/V2). Substrates for strand transfer alone are complementary 19 and
21 nucleotide oligomers representing end processed LTR DNA. Substrates for the disintegration assay are comprised of either four complementary oligomers
(Y oligomer substrate) or a single self-complementary oligonucleotide (db-Y1, dumbbell oligomer). Substrates were 5 end-labeled with 32P-dATP and
experiments performed with recombinant HIV IN in vitro as previously described (Chow, 1997).
Structures
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1996b). Intracellular inhibition of IN was demonstrated
through selection of an L-CA-resistant variant of HIV and
the subsequent isolation of a mutant virus containing a
mutation within IN, glycine 140 to serine (ING140S). This
mutation was sufficient to confer L-CA-resistance to other-
wise wild-type HIV, as demonstrated through sub-allelic
reconstruction of the mutant virus (King and Robinson,
1998). A recent report suggests that L-CA also blocks HIV
entry (Pluymers et al., 2000). L-CA belongs to a family of
compounds having a central carboxylated core and two
catechol rings. This group, the dicaffeoyltartaric acids, are
selective inhibitors of IN and do not inhibit the activity of
structurally-related metalloenzymes (McDougall et al.,
1998; Zhu et al., 1999). Recent molecular modeling predic-
tions (Sotriffer et al., 2000), based on the crystal structure of
an IN-inhibitor complex (Goldgur et al., 1999), have sug-
gested that L-CA fits into a drug binding pocket and fills the
entire catalytic groove of HIV IN.
The diketoacids are structurally distinct from L-CA and
its analogues yet share certain similarities, including a free
carboxylic acid and an adjacent carbonyl group (see Struc-
tures), which are required for activity (Hazuda et al., 2000;
King et al., 1999; Reinke et al., 2002). The similarity in
chemical constituents necessary for activity led to the hy-
pothesis that L-CA and the diketoacids fill the same binding
pocket. However, the diketoacids inhibit only strand trans-
fer (Espeseth et al., 2000; Hazuda et al., 2000), not 3 end
processing or disintegration, suggesting that they fit into the
drug binding pocket differently than L-CA.
The mechanism by which the ING140S mutation confers
resistance to L-CA has not been established. Additionally,
the effects of this mutation on viral integration and on IN
catalytic activity at the biochemical level have not been
examined previously. This report describes the effects of the
ING140S on viral replication and IN activity in vitro. Fur-
thermore, the effects of the G140S mutation on the suscep-
tibility of HIV to several anti-HIV agents, including
L-731,988 (Hazuda et al., 2000), a diketoacid, were studied
to determine whether resistance to L-CA and L-731,988
map to the same amino acid.
Results
HIV containing the IN G140S mutation is mildly
attenuated for replication
HIV containing the single amino acid change at glycine
140 of IN, HIVNL4-3:ING140S, is resistant to L-CA in vitro
and replicates slower than wild-type HIVNL4-3 (King and
Robinson, 1998). HIVNL4-3:ING140S replication in MT-2
cells was compared to reference HIVNL4-3 at equal reverse
transcriptase (RT) activity or equal fifty percent tissue cul-
ture infectious dose (TCID50). Viral replication was quan-
titated by RT release into the culture supernatant and by
immunofluorescence assay (IFA) (Fig. 2). HIVNL4-3:ING140S
displayed a slight delay in the time to infect 100% of MT-2
cells. This was almost entirely due to a delay in detection of
the virus during the first 36 h post inoculation. Delay was
not secondary to different amounts of input virus, as the
same delay was seen whether equal amounts of input
RT (10,000 cpm) or infectious virions (20,000 TCID50)
were used. As described previously, both HIVNL4-3 and
HIVNL4-3:ING140S were generated by sub-allelic recon-
struction and contained the silent mutations used to clone
the IN genes (King and Robinson, 1998).
The delay in replication appeared to be in the initial
hours post infection, as the slope of the growth curve for the
two viruses was the same or steeper for HIVNL4-3:ING140S.
These data suggested that a reversion or compensatory mu-
tation might have occurred. Virus was pelleted from MT-2
cells when the culture was 100% positive for HIV antigens
after two different inocula of the HIVNL4-3:ING140S. Both
inocula displayed a similar 12–18 h delay in the time to
infect 100% of the MT-2 cells. The virions were lysed and
the IN gene was amplified using reverse transcriptase poly-
merase chain reaction (RT-PCR). The IN genes from four
clones, two from each culture, were sequenced and no
mutations within IN were noted in any of the four clones.
These data are consistent with those obtained from multiple
experiments in which HIVNL4-3:ING140S remains stable in
H9 cells (King and Robinson, 1998, and data not shown).
Quantitative real-time polymerase chain reaction (PCR)
indicates a defect in integration
Equal amounts of HIVNL4-3 and HIVNL4-3:ING140S by RT
activity were inoculated onto H9 cells and the levels of
Fig. 2. Viral replication kinetics of HIVNL4-3 versus HIVNL4-3:ING140S.
MT-2 cells were infected with either HIVNL4-3 (●), or HIVNL4-3:ING140S
(E). Cultures were monitored for antigen production by IFA and virus-
associated RT activity every other day post infection (Robinson et al.,
1996b). Data points represent mean values of triplicate infections from
three experiments. Error bars represent one standard deviation. The per-
centages of HIV antigen positive cells at each time point post-infection are
indicated at each data point. Data shown is for infection with equal levels
of virus-associated RT activity. Similar results were obtained when equal
amounts of infectious particles for each virus were used (data not shown).
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cDNA and two LTR circle DNA were quantified by real-
time PCR. In Fig. 3A, the standard curve used to calculate
two LTR circle DNA is shown. The results are highly linear
(r2  0.992). In Fig. 3B, the total two LTR circle DNA in
infected cell equivalents for each virus is shown. There was
a statistically significant increase in two LTR circle DNA at
all timepoints after 12 h p.i. in the HIVNL4-3:ING140S com-
pared to the control virus, HIVNL4-3 (p  0.03). Figure 3C
illustrates the mean ratio of two LTR circle DNA to cDNA
from triplicate infections. HIVNL4-3:ING140S shows a higher
ratio of two LTR circle DNA to cDNA when compared to
HIVNL4-3, consistent with a failure in integration for
HIVNL4-3:ING140S. Nuclear entry is unaffected by the muta-
tion as two LTR circle formation occurs within the nucleus
(reviewed in Brown, 1997). Reverse transcription was un-
affected, as the kinetics of reverse transcription, as mea-
sured using real-time PCR and primers for early (AA55/
M667) and late (M661/M667) DNA products (Zack et al.,
1990), were the same for both viruses over the first 24 h of
infection (data not shown).
HIVNL4-3:ING140S is resistant to multiple IN inhibitors
HIVNL4-3:ING140S had been shown previously to be resis-
tant to L-CA: HIVNL4-3:ING140S was inhibited by L-CA no
more than 30% at any concentration (King and Robinson,
1998). When HIVNL4-3:ING140S was replicated in the pres-
ence of zidovudine, an RT inhibitor, both HIVNL4-3:ING140S
and HIVNL4-3 showed equal susceptibility (Fig. 4A), having
fifty percent effective concentrations (EC50) of approxi-
mately 20–40 nM. However, when the virus was replicated
in the presence of L-731,988, no EC50 was obtained (Fig.
4B). Indeed, there was some anti-HIV activity of L-731,988
but it plateaued at approximately 35% protection, nearly
identical to the results observed for L-CA (King and Rob-
inson, 1998). Furthermore, HIVNL4-3:ING140S and HIVNL4-3
were equally susceptible to other RT and protease inhibitors
(Fig. 5). Therefore, the ING140S mutation confers resistance
to both L-CA and L-731,988 but has no effect on the
susceptibility of the virus to inhibitors that act on other HIV
enzymes (Fig. 5).
Fig. 3. Ratio of two LTR circle DNA to cDNA by real-time PCR. Equal
amounts of HIVNL4-3:INWT versus HIVNL4-3:ING140S, as measured by RT
assay, were inoculated in triplicate onto H9 cells at a multiplicity of
infection of less than 1. 1  106 H9 cells were lysed at timepoints from 1
to 72 h p.i. The amounts of cDNA as measured by the M661/M667 primer
pair (Zack et al., 1990) and SYBR-I green dye and the relative levels of two
LTR circle DNA as measured by MH535/MH536 primer pair (Butler et al.,
2001) and SYBR-I green dye were determined. A)
Standard curve from six replicates used to calculate the levels of two LTR
circle DNA. Diluting cell lysate from 20,000-0 HIVLAI chronically-in-
fected H9 cells into the lysate of 0–20,000 H9 cells generated the standard
curve. The infected cell equivalents for each curve were 20, 40, 200, 400,
2000, 4000, and 20,000 infected cells in the DNA from a total of 20,000 H9
cells. Solid line is linear regression analysis (r2  0.992); the dashed lines
are the 95% confidence intervals. B) The levels of two LTR circle DNA at
each timepoint in infected cell equivalents. Closed circles, HIVNL4-3; open
circles, HIVNL4-3:ING140S. Points are the means of triplicate infections; the
error bars are one standard deviation. Statistical significance, if less than
0.05, is illustrated above each point and was determined by Student’s t test
assuming equal variances. C) To control for different levels of cDNA, the
ratio of two LTR circle DNA to cDNA was determined at each timepoint.
Ratios were calculated using the mean cDNA and mean two LTR circle
DNA levels calculated from triplicate infections. Closed circles, HIVNL4-3;
closed triangles, HIVNL4-3:ING140S.
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Purified ING140S is attenuated for catalytic activity
INWT and ING140S proteins were expressed and isolated
at greater than 90% purity as analyzed by SDS–PAGE and
Coomassie blue staining (data not shown). Purified IN pro-
teins were used at equal concentrations in the disintegration
assay. At each protein concentration tested, ING140S was
attenuated for disintegration activity compared to INWT
(Figs. 6A and 6B). Linear regression analysis, using molec-
ular activity data points for both proteins that were within
the linear range of measurement (INWT r2  0.98, ING140S
r2  0.98), demonstrated an approximately eight-fold reduc-
tion in disintegration activity of ING140S compared to INWT.
Similar attenuation of ING140S for 3 end processing, when
compared to INWT, was also observed (Figs. 7A and 7B).
To further analyze the mechanism of ING140S attenua-
tion, steady-state kinetic analyses of the disintegration re-
action were utilized. Amounts of INWT and ING140S proteins
that gave similar levels of disintegration activity, approxi-
mately 40% conversion of disintegration substrate to prod-
uct in 1 h at 37°C, were incubated with increasing concen-
trations of disintegration substrate, in excess of enzyme, and
the reaction progress measured at four, eight, and twelve
minutes (Figs. 8A and 8B). Reactions were performed at
least in triplicate with each reaction quantitated from dupli-
cate runs for a total of at least six replicates per data point.
Linear regression analysis was performed using data points
from each replicate on the Lineweaver-Burk plot (Fig. 8C)
to derive the mean Vmax and Km for each protein. INWT (35
nM) displayed a Km for disintegration substrate of 155 nM.
The Vmax for disintegration catalyzed by INWT was 3.5 
103 pmol product per pmol IN per minute. Marked enzy-
matic attenuation was observed when ING140S at 229 nM
was utilized. While the Km of ING140S for disintegration
substrate (124 nM) was not statistically different than wild-
type IN (P  0.461), the Vmax of ING140S catalyzed disin-
tegration was approximately five-fold lower (7.4  104
pmol disintegration product per pmol IN per minute). This
Fig. 4. HIVNL4-3:ING140S is resistant to L-731,988 but not zidovudine. Either HIVNL4-3 or HIVNL4-3:ING140S, was preincubated with H2O (virus control; 0%
viable) or varying concentrations of Panel A: zidovudine, or Panel B: L-731,988 for 1 h. Next, MT-2 cells were added and the virus and cells incubated for
four days before harvesting the cells to quantify HIV-induced cytopathic effect. Cells incubated in the absence of HIV were 100% viable. For both panels
each point is the mean of triplicate infections and error bars are one standard deviation. Susceptibilities of HIVNL4-3 from one experiment and HIVNL4-3:
ING140S from two experiments are given. Each experiment represents triplicate infections for a total of six separate infections. Anti-HIV assays were performed
essentially as described previously (King and Robinson, 1998). These results are consistent with those previously published for HIVNL4-3 and HIVNL4-3:
ING140S in the presence of zivodudine and L-CA (King and Robinson, 1998).
Fig. 5. HIVNL4-3:ING140S is resistant to IN inhibitors but not to RT or PR
inhibitors. Each virus was inoculated onto MT-2 cells in triplicate wells of
a 96 well plate in the presence of increasing concentrations of the indicated
anti-HIV compound. Cells were harvested and stained to determine pro-
tection from the lytic effects of HIV as described previously. Numbers
above each column are the number of replicate experiments used to
calculate the mean EC50. The actual number of infections is three times that
number. An asterisk represents a statistically significant difference in IC50.
Error bars are 1 SD. ZDV  zidovudine; DDC  dideoxycytidine; DDI 
dideoxyinosine; NLF  nelfinavir; L-CA  L-chicoric acid; DKA 
L-731,988. HIVNL4-3:IN7-3 is HIVNL4-3 with mutations for IN cloning.
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difference was statistically significant (P  0.00001) and is
also readily apparent on a Michealis-Menten plot (Fig. 8D).
Biochemical characterization of ING140S
In an attempt to determine the nature of the ING140S
enzymatic defect, optimal temperature and divalent metal
ion concentrations for both proteins were determined. Concen-
trations of mutant and wildtype IN proteins that gave similar
levels of disintegration activity (INWT  35 nM, ING140S 
229 nM) were utilized for these experiments. For INWT and
ING140S proteins, optimal disintegration activity was observed
at 30°C (not shown). Both INWT and ING140S displayed the
same preference for Mn2 over Mg2 in the disintegration
assay with less efficient catalysis in the presence of Mg2 (not
shown). Additionally, both wildtype and mutant IN proteins
displayed nearly identical concentration profiles for both Mn2
and Mg2 and were inactive with Zn2 (not shown).
To determine whether the ING140S enzymatic defect re-
sulted from a defect in binding to DNA, equal concentra-
tions of INWT and ING140S, or a non-specific protein, hen
egg lysozyme (HEL), were incubated with radiolabeled 3
end processing substrate, followed by filtration of the mix-
ture through a 0.45 m nitrocellulose filter. INWT and
Fig. 7. Molecular activity analysis of the 3 end processing and strand transfer reactions. Increasing concentrations of INWT and ING140S were incubated with
5 nM end processing/strand transfer substrate (V1/V2) for 1 h at 37°C. Panel A: Reactions were resolved by 15% denaturing PAGE. Lanes 1 and 2: 120 nM
INWT; lanes 3 and 4: 360 nM INWT; lanes 5 and 6: 120 nM ING140S; lanes 7 and 8: 360 nM ING140S. The closed arrow indicates the substrate (db-Y1); s.t.
indicates the position of strand transfer products; e.p. indicates the position of the band corresponding to end-processed product. Panel B: Quantification of
end processing products. Closed bars represent INWT and open bars represent ING140S. Data points are the means of at least duplicate experiments. Error bars
are one standard deviation.
Fig. 6. Molecular activity analysis of the disintegration reaction. Increasing concentrations of INWT and ING140S were incubated with 5 nM dumbbell
disintegration substrate (db-Y1) for 1 h at 37°C in duplicate. Panel A: Reactions were resolved by 15% denaturing PAGE. Lanes 1 and 2: 195 nM INWT;
lanes 3 and 4:240 nM INWT; lanes 5 and 6: 195 nM ING140S; lanes 7 and 8: 240 nM ING140S. The closed arrow indicates substrate (db-Y1) and the open arrow
indicates disintegration product. Panel B: Quantification of data from molecular activity experiments. Closed circles represent INWT and open circles represent
ING140S. Data points are the means of at least duplicate experiments. Error bars are one standard deviation.
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ING140S bound similar levels of DNA at equal protein con-
centrations, whereas HEL possessed much lower levels of
non-specific DNA binding (Fig. 9). Lower concentrations of
IN protein could not be used due to variability in non-
specific binding to membranes (data not shown).
ING140S is resistant to inhibition by IN inhibitors
We measured the sensitivity of INWT and ING140S to
L-CA and L-731,988 using IC50 analysis. For susceptibility
to L-CA, the disintegration assay was performed with both
proteins at equal levels of disintegration activity, in the
presence of increasing concentrations of L-CA, and the
level of inhibition using the Y -oligomer substrate at each
L-CA concentration was assessed. Triplicate reactions were
performed for each protein; each reaction was performed
using three replicates. As shown in Table 1, for each of the
nine replicates, ING140S disintegration activity was less sen-
sitive to inhibition by L-CA than INWT. Indeed, the mean
IC50 of L-CA against ING140S was nearly five-fold higher
than against INWT (82 nM vs 372 nM, respectively). This
difference was statistically significant (P 0.0001). Similar
Fig. 8. Steady-state kinetic analysis of the disintegration reaction. INWT at 35 nM or ING140S at 229 nM (similar activity levels) were incubated with increasing
concentrations of db-Y1. The initial velocity of the reaction at each substrate concentration was determined by measuring the amount of product produced
at 4, 8, and 12 minutes and a rate for each reaction was calculated. Panel A: Representative gel for INWT reactions. Panel B: Representative gel for ING140S
reactions. For Panels A and B, lane 1: 100 nM db-Y1; lane 2: 175 nM db-Y1; lane 3: 250 nM db-Y1; lane 4: 325 nM db-Y1; lane 5: 400 nM db-Y1; lane
6: 500 nM db-Y1. The closed arrow indicates substrate (db-Y1) and the open arrow indicates disintegration product. Time points for each reaction are
indicated above each gel. Panel C: Lineweaver-Burk plot for disintegration activities. Linear regression analysis (INWT r2  0.96, ING140S r2  0.99) was
utilized to determine Vmax and Km for both proteins. Closed circles represent INWT and open circles represent ING140S. Data points are means of triplicate
experiments, each quantitated from duplicate runs. Error bars are one standard deviation. Panel D: Michealis-Menten plot of the data illustrated in Panel C.
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results were obtained when INWT and ING140S proteins were
present in IC50 assays at equal protein concentrations (not
shown).
Because L-731,988 only inhibits strand transfer, IC50
analyses of INWT and ING140S in the strand transfer reaction
were performed in the presence of L-731,988. As shown in
Figure 10, ING140S was resistant to the anti-IN effects of
L-731,988. The IC50 of L-731,988 against the two proteins
were: INWT  825 nM; ING140S  3,009 nM (P  0.01).
This four-fold resistance is especially apparent at the high-
est concentrations of L-731,988 (Lanes 1–9), as the amount
of strand transfer product in panels A and B are nearly equal
despite five-fold less strand transfer product for ING140S
compared to INWT in the enzyme control lanes (Enz.). The
results for these two reactions are quantified and illustrated
in Fig. 10C and the mean of all reactions quantified and
shown in Fig. 10D. Therefore, the ING140S mutation confers
cross resistance between L-CA and L-731,988 of 4–5 fold
when compared to the reference protein. However, since the
G140S mutation severely attenuates the enzymatic activity
of the protein, it cannot be ruled out that the effect of the
G140S mutation on catalysis alone confers resistance to
both inhibitors.
Discussion
Mutation of critical residues of HIV IN results in atten-
uation of enzymatic function in vitro (Engelman and
Craigie, 1992; Leavitt et al., 1993) and viral replication in
tissue culture (Engelman et al., 1997; Taddeo et al., 1994).
There is often a lack of correlation between enzymatic
attenuation observed for mutant IN in vitro and the rate of
replication for mutant viruses. We have examined the ef-
fects of a previously isolated drug-resistance mutation,
ING140S, on viral replication, enzymatic activity, and drug-
resistance. ING140S, in the context of otherwise wild-type
HIV, shows a slight delay in replication compared to wild-
type virus (Fig. 2). However, when examining the effect of
this mutation on disintegration (Fig. 6) or end processing
and strand transfer (Fig. 7) activities of purified recombinant
IN under equilibrium conditions, a more dramatic effect was
observed. More importantly, these enzymatic defects confer
a defect in integration as measured by an increase in the
ratio of two LTR circles to cDNA in infected cells (Fig. 3).
Surprisingly, despite the effects of the mutation on integra-
tion, to date there has been no evidence that reversion
mutations occur in either MT-2 or H9 cells. However,
compensatory mutations in other viral genes may occur.
To further characterize the enzymatic attenuation af-
forded by the G140S mutation, as observed under equilib-
rium conditions, steady-state kinetic analysis was per-
formed with mutant and wild-type IN proteins (Fig. 8).
Fig. 9. HIV LTR DNA-binding by IN proteins. Equal concentrations of
INWT (filled bars), ING140S (open bars), or HEL were incubated with
32P-5-end-labeled V1/V2 substrate as described (Chow, 1997). Following
incubation the mixture was filtered through 0.45 m nitrocellulose filters,
extensively washed, and the filters dried. The extent of IN DNA binding
was quantitated by scintillation counting in the presence of liquid scintil-
lant. Bars are means of triplicate experiments with background binding of
DNA to HEL subtracted. Error bars are one standard deviation.
Table 1
















1 70b 62 79 340 285 287
2 108 89 99 633 423 633
3 72 79 78 170 260 313
Mean  82 nMc; SD  15 nM Mean  372 nMc; SD  163 nM
a INWT or ING140S was incubated with the “Y”-oligomer disintegration substrate in the presence of increasing concentrations of L-CA for one hour at 37°C
as described (King et al., 1999). Following 15% denaturing PAGE, the amount of disintegration substrate produced under each condition was determined
by PhosphorImager analysis. IC50 were calculated utilizing the CalcuSyn for Windows software package (BioSoft). Data shown are for experiments where
INWT and ING140S were present at levels that gave similar levels of disintegration activity (INWT  25 nM, ING140S  195 nM). Similar results were obtained
when equal protein concentrations were utilized (data not shown).
b IC50 in nM.
c P  0.0001.
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Although disintegration activity has not been observed in
vivo, mutations that affect disintegration activity also inter-
fere with end processing and strand transfer activities of IN
(Mazumder et al., 1994; van Gent, et al., 1992). Disintegra-
tion using the dumbbell substrate is also less likely to
complicate steady-state kinetic analyses as only one com-
plex, E  S, is likely to exist. Furthermore, only one
product, rather than several, is formed. Finally, most com-
pounds that inhibit disintegration in vitro also inhibit the 3
end processing and strand transfer activities of IN in vitro
(Farnet et al., 1998; Neamati et al., 1997; Neamati et al.,
1998; Reddy et al., 1999; Robinson et al., 1996a; Robinson
et al., 1996b). Thus, disintegration is a useful measure of IN
activity and is the enzymatically-mediated reversal of the
strand transfer reaction. The diketoacids are relatively se-
lective inhibitors of strand transfer, rather than end process-
ing or disintegration (Hazuda et al., 2000). It has been
hypothesized that the diketoacids bind to the host DNA
binding site, rather than to the viral DNA binding site
(Hazuda et al., 2000). Our results on cross-resistance, cou-
pled with previously published findings that L-CA blocks
both catalysis and strand transfer (Robinson et al., 1996a;
Robinson et al., 1996b), would suggest that L-CA may alter
both the host DNA and viral DNA binding sites but not
substrate binding affinity.
A strong correlation between attenuation of end process-
ing and strand transfer and disintegration was observed for
both INWT and ING140S (Figs. 6 and 7). Steady-state kinetic
analyses using retroviral IN’s have been performed previ-
ously (Chow and Brown, 1994b; Jones et al., 1992; Tramon-
tano et al., 1998; Zhu et al., 1999); therefore, we reasoned
that steady-state kinetic analysis could be used to better
understand the effect of mutations on IN. Our results cor-
relate well with steady state kinetic analyses of other IN
proteins. A decrease in the velocity of the disintegration
reaction catalyzed by ING140S (Fig. 8) was observed, sug-
Fig. 10. ING140S is resistant to L-731,988. Panel A) 3 end processing and strand transfer assays with the INWT protein. Panel B) 3 end processing and strand
transfer assays with ING140S protein. Concentrations of L-731,988, in M, are given above each triplicate reaction. (), 25 M L-731,988: Lane 21 ():
25 M L-tartaric acid; (Enz.), substrate with IN; S  substrate with no enzyme; Reactions were performed using recombinant IN, V1/V2 substrate for 1 h
at 37°C. Strand transfer products (STP) were separated from substrate (arrow) by denaturing SDS-PAGE. Both panels were incubated together on the
PhosphorImager and the percent inhibition of strand transfer products, irrespective of enzyme activity, were calculated. Each image was adjusted at the same
time to the same level; therefore, product intensities are directly comparable. This result is representative of three experiments. Panel C) quantification of the
results from Panels A and B (one triplicate reaction). Panel D): the mean quantification for all nine replicates (three assays performed in triplicate) used to
calculate the IC50. P values were calculated at each point using student’s unpaired t test assuming equal variances. *P  0.05; **P  0.005; ***P, 0.0005.
For Panels C and D: Closed circles are INWT, open circles are ING140S; each point is the mean; the error bars are one SD. Lines were generated using linear
regression analysis; r2 for each line are given on each graph.
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gesting that the effect of the G140S mutation was at catal-
ysis, rather than substrate binding, as similar concentrations
of wild-type and mutant IN’s bound virtually equal amounts
of HIV LTR oligonucleotide DNA (Fig. 9). The steady-state
kinetic results in combination with the LTR binding results
suggest that similar levels of actively-folded protein were
present for both wild-type and mutant IN, and that impaired
catalysis of ING140S alone accounts for the defect in its
enzymatic activities. However, we cannot rule out the pos-
sibility that the mutation affects IN multimerization or fold-
ing, which could affect catalysis without affecting DNA
binding, or that these results might not be more profound at
physiologically relevant low protein levels, since ING140S at
the lowest protein concentrations demonstrated the most
pronounced, yet statistically insignificant, effect on DNA
binding. The level of attenuation observed for ING140S is
consistent with that reported for disintegration activity me-
diated by the core catalytic domain of an ING140A mutant
(Greenwald et al., 1999). Finally, the increase in formation
of two LTR circles during replication of HIV containing this
mutation (Fig. 3) is consistent with effects of the mutation
on catalysis but not cellular entry, reverse transcription, or
nuclear import of the viral genome. Abortive integration
(Fig. 3) may be responsible for the delay in HIV replication
seen in both MT-2 cells (Fig. 2) and H9 cells (King and
Robinson, 1998), especially since the delay in MT-2 cells
(Fig. 2) correlated with the maximum increase in two LTR
circle DNA to cDNA ratio in H9 cells (Fig. 3).
The glycine at position 140 of HIV IN is phylogeneti-
cally conserved (Kulkosky et al., 1992). From the crystal-
lographic structure of the catalytic core domain of HIV IN
(Dyda et al., 1994; Goldgur et al., 1998; Maignan et al.,
1998), this glycine appears to act as a crucial anchor resi-
due. It is the final residue within an ordered -sheet, 5,
directly adjacent to a disordered loop domain, 4, amino
acids 141 to 149. The importance of this residue as an
anchor for the disordered loop was recently demonstrated
through site-directed mutagenesis (Greenwald et al., 1999).
Several structures suggest that G140 is an anchor for the
5–4 junction and lies near the putative active site, adja-
cent to the region in which the divalent metal ion is com-
plexed (Goldgur et al., 1998; Maignan et al., 1998). The
small side chains of G140 and G149 of IN may allow the
disordered loop to fold towards the face of the catalytic core
domain and are postulated to aid in the coordination of
divalent cation and formation of the active IN catalytic site
(Greenwald et al., 1999). The cycling between active and
inactive conformations that may involve movement of the
disordered loop is proposed to be critical in the IN catalytic
cycle (Asante-Appiah et al., 1998; Asante-Appiah and
Skalka, 1997) and is supported by the crystallographic data:
this region has high temperature factors (Greenwald et al.,
1999), suggesting it is flexible (Goldgur et al., 1998; Maig-
nan et al., 1998). Substitution of larger polar or non-polar
side chains at the site of the molecular hinge may result in
decreased ease of native conformational movements. In this
manner, the ING140S may directly result in loss of catalytic
activity of IN. The crystal structures of ING140A, ING149A,
and the double mutant display subtle alterations in morphol-
ogy, with increased rigidity in the disordered loop and
altered enzymatic activity (Greenwald et al., 1999).
In accordance with the hinge model, the effects of mu-
tation of either G140 or G149 should be limited to catalytic
activities and should not involve protein stability or sub-
strate binding. In support of this prediction, no dispropor-
tionate decreases in ING140S catalytic activity were observed
at increased or decreased temperatures when compared to
wild-type IN (not shown), suggesting that IN protein sta-
bility is not affected by this mutation. The catalytic core
domain of IN has previously been shown to be important in
the specific recognition of viral DNA near the conserved
CpA dinucleotide (Shibagaki and Chow, 1997), while cross-
linking studies have identified loop amino acids which make
direct contacts with substrate DNA molecules (Heuer and
Brown, 1998; Jenkins et al., 1997). However, no significant
difference in HIV LTR binding between ING140S and INWT
was observed (Fig. 9). These results are in agreement with
steady-state kinetic analysis (Fig. 7) in which the Vmax of
ING140S is decreased with no change in the apparent affinity
of this mutant for db-Y1 as measured by the Km. Our
observations combined with those of Greenwald et al.,
(1999) suggest that G140 has little effect on either specific
recognition of viral DNA or target DNA binding.
Utilizing IC50 analyses we have demonstrated an approx-
imately four-fold decrease in sensitivity of purified recom-
binant ING140S to L-CA and to L-731,988 when compared
to wild-type IN (Table 1 and Fig. 10). Although this is a
modest effect on inhibitor susceptibility observed in vitro,
the direct effects of this mutation on inhibitor-susceptibility
have been observed in vivo (King and Robinson, 1998)
(Fig. 4). This resistance phenotype was limited to IN inhib-
itors (Fig. 5). Computer analysis of the crystal structure of
an ASV IN:inhibitor complex (Lubkowski et al., 1998),
with an analogous glycine to serine mutation modeled into
the structure, suggests that this mutation would reduce the
size of the drug binding pocket (King, P.J., Poulos, T., and
Robinson, W.E., Jr. unpublished results). Thus, the muta-
tion alone may occlude the binding of L-CA and L-731,988
by size alone. Our results suggest that ING140S is, at least in
part, directly responsible for conferring IN inhibitor-resis-
tance to mutant HIV. Similar attenuation of viral growth,
enzyme function, and degree of inhibitor resistance were
reported for HIV resistant to the diketoacids (Hazuda et al.,
2000).
Recent data suggest that IN containing mutations at phe-
nylalanine 185 (F185K), cysteine 280 (C280S), and glycine
140 (G140S) was no more resistant to L-CA than a protein
containing just the F185K and C280S mutations (Pluymers
et al., 2000). However, the IC50 of L-CA against IN con-
taining the F185K and C280S mutations in the disintegra-
tion reaction was 2.0 M, approximately 12-fold higher
than reported by our laboratory and others (Farnet et al.,
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1998; Robinson et al., 1996a; Robinson et al., 1996b; Zhu et
al., 1999). Thus, the wild-type IN was more resistant to the
effects of L-CA than the ING140S mutant IN. The mecha-
nisms by which the F185K and/or C280S mutations confer
resistance to L-CA should be further evaluated.
The G140S mutation confers cross-resistance to
L-731,988. Furthermore, resistance mutations for
L-731,988 (Hazuda et al., 2000) are similar to residues
predicted to form the L-CA binding pocket (Robinson et al.,
1996a; Sotriffer et al., 2000). More recently, Sotriffer et al.
(2000) utilized computational docking to demonstrate that
L-CA more completely fills an inhibitor-binding groove
than do other IN inhibitors. Such docking experiments sug-
gested that L-CA interacts with lysines 156 and 159, as well
as cysteine 65, threonine 66, histidine 67, glutamine 148,
and glutamate 152. The most favorable contacts are gluta-
mate 152, a member of the catalytic triad, and glutamine
148 (Sotriffer et al., 2000). These results are quite similar to
previously reported docking experiments utilizing a differ-
ent crystal structure and an alternative docking program
(Robinson et al., 1996a). To date the binding pocket for
L-731,988 and other diketoacids has not been described.
The cross-resistance data support the hypothesis that one
drug binding pocket exists for dicaffeoylquinic acids, dicaf-
feoyltartaric acids, and diketoacids. Furthermore, position
140 of integrase is an important residue both for suscepti-
bility of the protein to inhibition by several classes of
inhibitor and for catalysis but conservation of the glycine




MT-2 cells are CD4 T-lymphoblastoid cells that are com-
pletely lysed by X4 isolates of HIV. HIVNL4-3 and HIVNL4-3
containing the G140S IN mutation (HIVNL4-3:ING140S) were
obtained as described (King and Robinson, 1998) (HIVNL4-3
GenBank #M19921; HIVNL4-3:ING140S GenBank #AF078150).
Briefly, following selection under L-CA, the reference IN
sequence was replaced by IN containing only the G140S sub-
stitution. Plasmids were subsequently transfected into HeLa
cells, the cells were washed, and then cultured with H9 cells, a
CD4 T-lymphoblastoid cell line that supports chronic infec-
tion by HIV. Virus was obtained when H9 cells became 100%
positive for HIV antigens by IFA. Cells were grown in RPMI-
1640 containing 25 mM 4-(2-hydroxyethyl)-1-pipera-
zineethanesulfonic acid and supplemented with 11.5% fetal
bovine serum (Gemini Biosciences) and 2 mM L-glutamine.
All HIV were obtained from H9 cell culture supernatants
clarified of cells by low speed centrifugation followed by
filtration through 0.45 m cellulose acetate filters.
Viral quantification
HIV was quantified using three separate assays. (1) RT
activity. Virus-associated RT was measured as [3H]dTTP
incorporation into a poly(rA)-oligo(dT) template by a
modification (Robinson et al., 1989) of a method de-
scribed by Poeisz et al. (1980). (2) TCID50. The numbers
of infectious particles were determined by endpoint di-
lution analysis on MT-2 cells in replicates of eight. End-
points were measured after 21 days (greater than seven
replicative cycles). The TCID50 represents one infectious
particle per inoculum and is reported as the number of
infectious particles per ml of culture fluid (Robinson et
al., 1989). (3) IFA. The percent of cells expressing HIV
antigens was enumerated using methanol:acetone-fixed
cells incubated first with human polyclonal anti-HIV-1
pooled immunoglobulin fraction followed by fluorescein-
ated goat anti-human IgG as described (Robinson et al.,
1989).
Susceptibility of molecular clones to anti-HIV agents
The resistance profile of HIVNL4-3:ING140S to L-CA has
been described, previously (King and Robinson, 1998).
HIVNL4-3:ING140S, HIVNL4-3:IN7-3 containing the silent clon-
ing mutations and IN from HIV multiply-passaged in tissue
culture (King and Robinson, 1998), and HIVNL4-3 were
incubated in triplicate with increasing concentrations of
zidovudine, dideoxycytidine, dideoxyinosine, nelfinavir,
L-CA, or L-731,988 for one h at 37°C. Next, MT-2 cells
were added and the cells harvested for HIV-induced cyto-
pathic effect four days later (King et al., 1999; King and
Robinson, 1998; Montefiori et al., 1988; Robinson et al.,
1996a; Robinson et al., 1996b). Cells were reduced by 50%
and re-fed without additional anti-HIV compound on day
two.
Cell lysis and sample preparation for real-time PCR
At each time point 1.0  106 cells were lysed in 100 l
of a lysis solution composed of equal parts solution A (100
mM KCl, 10 mM Tris-HCl pH 8.3, 2.5 mM MgCl2) and
solution B (10 mM Tris-HCl pH 8.3, 2.5 mM MgCl2, 1%
Tween-20, 1% Nonidet P40 and 20 g of proteinase K per
1.0  106 cells. Cells were lysed at 65°C for 1 h, followed
by heat-inactivation of proteinase K at 95°C for 15 minutes
(Kellogg and Kwok, 1990).
Real-time PCR and oligonucleotide primers:
Primers were: AA55: 5-CTGCTAGAGATTTTCCA-
CACTGAC-3 (HIV-1LAI anti-sense 635–612) M667: 5-
GGCTAACTAGGGAACCCACTG-3 (HIV-1LAI sense
496 –516) M661: 5-CCTGCGTCGAGAGAGCTCCTC-
TGG-3 (HIV-1LAI anti-sense 695–672) MH535: 5-AA-
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CTAGGGAACCCACTGCTTAAG-3 (HIV-1LAI sense
9683–9697) MH536: 5-TCCACAGATCAAGGATATCT-
TGTC-3 (HIV-1LAI anti-sense 58–21)
Real-time PCR was performed using the Cepheid Smart
Cycler (Fisher Scientific, Tustin, CA). PCR conditions
were: initial denaturation at 95°C for 150 s followed by 40
rounds of cycling at 95°C for 15 s, then 61°C for 30 s. Each
PCR reaction contained 0.2 M each of dATP, dCTP,
dGTP and dTTP, 1.5 mM MgCl2, 20 mM Tris-HCl pH 8.4,
50 mM KCl, 0.625 U Taq DNA polymerase (GIBCO-BRL),
0.2 M of each primer, and 0.25 SYBR-I Green (Sigma-
Aldrich or Molecular Probes) and 2 l of cell lysate in a 25
l reaction volume. Following amplification, melt curve
analysis between 60°C to 95°C (0.2°C/s) was performed to
determine the Tm of the amplified product. The Tm of each
reaction was compared to control reactions. Products with
incorrect Tm contain primer dimers and are below the sen-
sitivity of real-time PCR. HIV-1 specific primers pairs were
used to detect minus strand strong stop, AA55/M667 (Zack
et al., 1990), complete cDNA, M661/M667 (Zack et al.,
1990), and two LTR circle DNA, MH535/MH536 (Butler et
al., 2001). For two LTR circle DNA, PCR conditions were
as described previously (Reinke et al., 2002): initial dena-
turation at 95°C for 150 s., followed by 40 rounds of cycling
at 95°C for 15 s., then 59°C for 30 s. Following amplifica-
tion, melt curve analysis between 60°C and 95°C (0.2°C/s)
was performed to determine the Tm of the amplified prod-
uct. Each PCR reaction contained 0.2 M of each dNTP,
1.5 mM MgCl2, 20 mM Tris-HCl pH 8.4, 5 g non-acety-
lated BSA, 0.15 M trehalose, 0.2% Tween-20, 0.625 U Taq
DNA polymerase (GIBCO-BRL), 0.2 M of each primer,
MH535 and MH536 (Butler et al., 2001), and 0.25
SYBR-I Green and 2 l of cell lysate in a 25 l reaction
volume. All results were calculated as infected cell equiv-
alents from standard curves using 20,000 to 20 HIVLAI
chronically infected H9 cells diluted into the DNA from
20,000 uninfected H9 cells.
Viral replication
Equal amounts of HIVNL4-3 and HIVNL4-3:ING140S by RT
(10,000 cpm) or TCID50 (20,000) were used to infect 5 
105 MT-2 cells in triplicate wells of a 24-well plate (Costar).
After 24 h at 37°C, cells were removed, washed, and re-
plated. Culture supernatant fluid was removed from each
well every other day and virus quantitated by RT release.
Half of the cells were removed every other day and assayed
by IFA to determine the number of HIV antigen positive
cells.
Purification of recombinant IN
IN sequences from HIVNL4-3 and HIVNL4-3:ING140S were
amplified by PCR using oligonucleotide primers, then in-
troduced into a pET-based, Escherichia coli expression vec-
tor, as described previously (King and Robinson, 1998;
Vincent et al., 1993). Purification of amino terminus six
His-IN fusion proteins by Ni2 affinity column chromatog-
raphy was performed as described (King et al., 1999). Pro-
tein purity was assessed by sodium dodecylsulfate-poly-
acrylamide gel electrophoresis (SDS–PAGE) followed by
Coomassie R250 staining. Imidazole fractions chosen for
enzymatic analysis contained peak protein concentrations
migrating at approximately 32,000 Da, and were greater
than 90% pure.
Molecular activity analysis
The activity of purified recombinant IN was measured in
the disintegration reaction, using the db-Y1 “dumbbell”
substrate (Chow and Brown, 1994a) and in the 3 end
processing reaction using the V1/V2 substrate as described
(Chow, 1997). Briefly, 5 nM of substrate was added to
reactions containing equal concentrations of reference
(INWT) or mutant (ING140S) proteins. The reactions were
allowed to proceed for 1 h at 37°C and then were stopped by
the addition of ethylenediaminetetraacetic acid (EDTA) to a
final concentration of 18 mM, and the reactions placed on
ice. Oligonucleotides were resolved by 15% PAGE contain-
ing 7M urea. Gels were dried and quantitated by Phospho-
rImager analysis using ImageQuant Software.
Steady-state kinetic analysis
INWT (35 nM) or ING140S (229 nM) were utilized in the
disintegration reaction in the presence of db-Y1 at 100, 175,
250, 325, 400, and 500 nM. Reaction progress was mea-
sured at 4, 8, and 12 minutes by removing a portion of the
reaction mixture, adding EDTA to a final concentration of
18 mM, and placing the sample on ice. Reaction progress at
each time point for each substrate concentration was quan-
titated by PhosphorImager analysis. Initial velocities for
each substrate concentration were defined as the slope of the
progress curve (mol product per minute per mol IN).
50% inhibitory concentration (IC50) analysis
IC50 of L-CA against both INWT and ING140S in the
disintegration reaction using the Y-oligomer substrate were
performed with IN at equal molecular activities. INWT was
present at 25 nM and ING140S present at 195 nM in these
experiments. For IC50 analyses of L-731,988, 250 nM INWT
and 200 nM ING140S were incubated with increasing con-
centrations of L-731,988 and 10 nM V1/V2 substrate. The
amount of product formed at increasing L-CA concentra-
tions in the disintegration reaction or increasing L-731,988
concentrations in the strand transfer reaction over 1 h at
37°C were determined by PhosphorImager analysis follow-
ing 15% denaturing PAGE.
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Temperature-dependence and divalent metal ion usage
The disintegration reaction using purified recombinant
INWT (35 nM) and ING140S (230 nM) was performed with
db-Y1 at increasing temperatures (20, 24, 27, 30, 37, 42,
and 50°C), or at 37°C in the presence of 1, 2.5, 5, 10, 15, 20,
and 40 mM MnCl2, or 2.5, 5, 10, 15, 20, and 40 mM MgCl2
or ZnCl2. The amount of disintegration product formed by
each enzyme under each condition in 1 h was determined by
PhosphorImager analysis following 15% denaturing PAGE.
DNA-binding assay
Equal concentrations of INWT and ING140S or HEL were
incubated with 32P end-labeled 3 end processing substrate
(V1/V2) and DNA binding was assessed by binding to
nitrocellulose filters as described (Chow, 1997). Bound
DNA was measured by liquid scintillation counting (Scinti-
Verse II, Fisher Scientific). Background binding of substrate
by HEL at each concentration was subtracted.
PhosphorImager analysis
Dried denaturing polyacrylamide gels were exposed on a
phosphor screen (Molecular Dynamics). Gels were removed
and the screens scanned on a Molecular Dynamics Storm
PhosphorImager. Quantification was performed using Mo-
lecular Dynamics ImageQuant. Gels were exposed for times
that gave peak PhosphorImager units within the linear range
of the phosphor screen (100,000 units).
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